(Boursier.com) — DBV Technologiesclinical-stage biopharmaceutical company, today announced its upcoming participation in the hybrid, in-person and virtual Annual Scientific Meeting of the European Academy of Allergy and Clinical Immunology, EAACI), which will be held from July 1 to 3, 2022 in Prague, Czech Republic. Czech.
Two scientific presentations were accepted, including a non-clinical poster and an oral presentation. DBV Technologies will also organize a symposium and will have a stand in the exhibition hall of the congress.

The data to be presented will focus on the direct and indirect costs of peanut allergy in households with peanut-allergic children aged 4-11 years in Germany, France and the UK. In addition, DBV Technologies will present an innovative approach to predict the results of an oral peanut challenge test using a new basophil activation test (BAT) and serum parameters as a potential biomarker of oral challenge results. These data may help inform the diagnosis of food allergy and potentially introduce a new approach to predict oral challenge test results for patients participating in immunotherapy clinical trials.

“The data we are presenting at EAACI this year highlights the enormous burden that families and patients with food allergies carry on a daily basis,” said Dr. Pharis Mohideen, medical director of DBV Technologies. “There is an urgent and unmet medical need for treatment options for food allergies, and innovations in this area, such as predictive biomarkers in clinical trials, could one day improve the quality of life for this population. I look forward to hearing that we are going to engage in in-depth discussions on these issues.